Here’s a story that has absolutely blown up this week. Eli Lilly secured FDA expanded access approval for a single patient to receive retatrutide - a drug that hasn’t been approved for anyone yet. The patient was identified only as a 79-year-old. And the internet has been losing its mind trying to figure out who it is.
The story, first reported by STAT News, has become one of the most talked-about GLP-1 stories of 2026. Not because of the science - though the science is interesting - but because of what it reveals about how experimental drugs get to patients before they’re officially available.
What Actually Happened
The FDA’s expanded access program (sometimes called “compassionate use”) allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials. It’s not new. The program has existed for decades and has been used for everything from experimental cancer treatments to unapproved antibiotics.
What made this case unusual was the speed and specificity. Eli Lilly filed an expanded access application for retatrutide, and the FDA approved it for one individual patient. The filing described a 79-year-old with obesity-related health conditions.
STAT News reported the story, and within hours, speculation erupted about the patient’s identity. The White House issued a denial that the application was filed on behalf of any government official. Multiple news outlets - Gizmodo, Slate, New York Magazine, the International Business Times - picked up the story. By the end of the day, it was trending across social media.
Why Retatrutide Matters
Lost in the noise is why someone would go to these lengths to get retatrutide specifically.
Retatrutide is Eli Lilly’s triple-agonist peptide. It targets three receptors simultaneously: GLP-1, GIP, and glucagon. That’s a different mechanism from semaglutide (Ozempic/Wegovy), which hits only GLP-1, and tirzepatide (Mounjaro/Zepbound), which hits GLP-1 and GIP.
In clinical trials, retatrutide has produced weight loss figures that exceed anything else in the pipeline. The Phase 2 data presented at ADA 2026 showed significant reductions in body weight, with some participants losing more than 20% of their starting weight. The compound is currently in Phase 3 trials, with results expected in late 2026 or early 2027.
For someone with serious obesity-related health conditions, retatrutide represents the most potent option that exists - but it’s not approved yet. The expanded access route is the only legal way to get it outside of a clinical trial.
The Expanded Access Question
The expanded access program is designed for exactly this kind of situation: a patient with a serious condition, an investigational drug that might help, and no satisfactory alternatives. In theory, it’s a good system.
In practice, it raises some uncomfortable questions.
Expanded access applications require a physician to file on behalf of a specific patient. The drug company has to agree to supply the drug. The FDA has to approve the application. It’s a process that favours patients with connections - to specialist physicians, to pharmaceutical companies, to the regulatory system itself.
Most people with obesity-related health conditions don’t have a physician who can navigate the expanded access process. Most don’t know the program exists. And most drug companies aren’t inclined to supply experimental drugs to individual patients outside of trials, because it creates reporting obligations and potential safety liabilities.
The retatrutide case has put a spotlight on these inequities. If one person can get an unapproved drug through expanded access, why can’t others in similar medical situations?
What the Research Says
The clinical data on retatrutide is genuinely impressive. A 2024 study published in the New England Journal of Medicine showed that retatrutide produced dose-dependent weight loss of up to 24.2% at 48 weeks in participants with obesity. That’s a higher figure than anything seen with semaglutide or tirzepatide at comparable timepoints.
The triple-agonist mechanism appears to produce effects that go beyond what GLP-1 agonism alone can achieve. The glucagon receptor component may contribute to increased energy expenditure, while the GIP component appears to enhance the weight loss effects of GLP-1 stimulation.
Phase 3 trials (NCT05929787 and related studies) are currently enrolling. These trials will determine whether the Phase 2 results hold up in larger, more diverse populations. If they do, retatrutide could become the most effective weight management compound ever developed.
The Australian Context
For the Australian research community, the expanded access story is relevant for a couple of reasons.
First, retatrutide is not approved by the TGA. It’s not available through any legal channel in Australia - not through prescription, not through compounding pharmacies, not through any pathway. Anyone selling “retatrutide” in Australia is selling an unapproved product with no quality assurance.
Second, the expanded access program doesn’t have a direct equivalent in Australia. The TGA’s Special Access Scheme allows access to unapproved therapeutic goods, but the process and criteria are different from the FDA’s program. The Australian system is generally more restrictive for this kind of individual access.
Third, the story highlights the demand that exists for next-generation compounds. When the most effective treatment isn’t available through legal channels, some people will seek alternatives - and that’s where the grey market becomes a problem. We’ve already seen this play out with counterfeit retatrutide products causing harm in Australia.
What to Watch
The expanded access story will probably fade from the news cycle in a few days. But the underlying questions won’t go away.
Watch for:
- Phase 3 retatrutide data - expected in late 2026 or early 2027. This will determine whether the drug gets FDA approval and eventually TGA approval.
- Expanded access policy debates - the retatrutide case may prompt calls for reform of the FDA’s expanded access program, particularly around equity of access.
- Australian regulatory timeline - if retatrutide is approved in the US, the TGA review process will begin. Historical timelines suggest 12-18 months from US approval to Australian availability.
- Grey market activity - high-profile stories about experimental drugs tend to drive demand on unregulated channels. The community should be aware of the risks.
The bottom line: retatrutide is a genuinely promising compound with clinical data that exceeds current options. But it’s not approved yet, and the expanded access case has exposed real inequities in how experimental treatments reach patients. For the Australian research community, the key message remains the same - wait for proper regulatory approval, and be very cautious about unregulated products claiming to be retatrutide.
Sources
Source: STAT News - Eli Lilly secures expanded access for retatrutide Source: Gizmodo - Who is the mystery 79-year-old patient? Source: New England Journal of Medicine - Retatrutide Phase 2 trial (2024) Source: ClinicalTrials.gov - Retatrutide Phase 3 studies
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.